The Week in Review: Holiday Transactions and Awards

Fosun Pharma will raise up to 635 million RMB ($93.4 million) to fund new projects; Nextchem Pharma has reopened after receiving new capital from NEA China and BioVeda; Syngenta Biotech committed $100 million to a new Beijing R&D center; Hutchison Chi-Med will collaborate with Cambridge University on the mechanism of a TCM; Hard to Treat Diseases plans to sell its cancer research initiative to a large TCM company; Alvogen opened a Shanghai office to sell products as well as source APIs and finished products; Astellas Pharma of Japan received SFDA approval for Vesicare®, a treatment for Overactive Bladder; Sinovac Biotech (北京科兴生物制品有限公司) was selected one of China's Top 10 most competitive companies listed overseas for 2009; and WuXi PharmaTech’s (药明康德) and Sundia MediTech (桑迪亚医药技术（上海）有限公司 were named to the 2009 Fast 500 Asia Pacific list. More details... Stock Symbols: (SHEX: 600196) (AIM: HCM) (OTC Pink Sheets: HTDS) (NSDQ: SVA) (NYSE: WX)